Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring

Clinical Pharmacokinetics

Volumn 53, Issue 8, 2014, Pages 753-762

  Pai, Manjunath P ^a   Cojutti, Piergiorgio ^b,c   Pea, Federico ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; AREA UNDER THE CURVE; ARTICLE; BLOODSTREAM INFECTION; BODY MASS; BODY SIZE; BODY WEIGHT; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MONITORING; HEIGHT; KIDNEY FUNCTION; MORBID OBESITY; PRIORITY JOURNAL; PROBABILITY; RESPIRATORY TRACT INFECTION; SKIN INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ADULT; BAYES THEOREM; BIOLOGICAL MODEL; BODY SURFACE; COMPLICATION; DOSE RESPONSE; FACTUAL DATABASE; FEMALE; HUMAN; KIDNEY FUNCTION TEST; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MONTE CARLO METHOD; OBESITY, MORBID; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; BODY MASS INDEX; BODY SURFACE AREA; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; IDEAL BODY WEIGHT; KIDNEY FUNCTION TESTS; LEVOFLOXACIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OBESITY, MORBID; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84905051119     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0154-1     Document Type: Article

References (46)

1. Gallus S, Odone A, Lugo A, et al. Overweight and obesity prevalence and determinants in Italy: an update to 2010. Eur J Nutr. 2013;52(2):677-85.
2. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14(1):9.
3. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-7.
4. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889-91.
5. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37(3):333-40.
6. Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg. 2011;92(4):1420-6.
7. Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970-6.
8. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081-91.
9. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634-49.
10. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535-65.
11. Michot JM, Seral C, Van Bambeke F, et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother. 2005;49(6):2429-37.
12. Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127-67.
13. Cook AM, Martin C, Adams VR, et al. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55(7):3240-3.
14. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16.
15. Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet. 2003;42(6):589-98.
16. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42(5):1098-104.
17. Drusano GL, Preston SL, Gotfried MH, et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2002;46(2):586-9.
18. Kashuba AD, Ballow CH, Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother. 1996;40(8):1860-5.
19. Dumond JB, Nicol MR, Kendrick RN, et al. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012;51(12):809-22.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
21. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53-62.
22. Devine B. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-5.
23. Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643-7.
24. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65.
25. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
26. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856-68.
27. ®, prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/021721s020-020635s57-020634s52-lbl.pdf. Accessed 13 May 2014.
28. Zhang J, Xu JF, Liu YB, et al. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother. 2009;15(5):293-300.
29. Alghanem S, Paterson I, Touw DJ, et al. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother. 2013;68(6):1338-47.
30. Emamian SA, Nielsen MB, Pedersen JF, et al. Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. AJR Am J Roentgenol. 1993;160(1):83-6.
31. Akpinar IN, Altun E, Avcu S, et al. Sonographic measurement of kidney size in geriatric patients. J Clin Ultrasound 2003;31(6):315-8.
32. Glodny B, Unterholzner V, Taferner B, et al. Normal kidney size and its influencing factors: a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol. 2009;9:19.
33. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87.
34. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505-8.
35. McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319-30.
36. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66(7):642-8.
37. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45(10):2793-7.
38. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003;17(3):529-43.
39. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279(2):125-9.
40. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209.
41. Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784-92.
42. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404-10.
43. Kato M, Takada S, Ogawara S, et al. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995;39(9):1979-83.
44. Pham L, Christensen JM, Rodriguez-Proteau R. Pharmacokinetic prediction of levofloxacin accumulation in tissue and its association to tendinopathy. Pharmacol Pharm. 2013;4:121-31.
45. Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance: what's dosing got to do with it? Crit Care Med. 2008;36(8):2433-40.
46. Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8(1):5-12.